Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 91.0%

Neg 91% Neu 0% Pos 0%

Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.